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Abstract
Activation of photosensitizers in endosomes enables release of therapeutic macromolecules into 
cytosol of the target cells for pharmacological actions. In this study, we demonstrate that direct 
conjugation of photosensitizer to oligonucleotides (ONs) allows spatial and temporal co-
localization of the two modalities in the target cells, and thus leads to superior functional delivery 
of ONs. Further, light-activated delivery of an anticancer ON caused cancer cell killing via 
modulation of an oncogene and photodynamic therapy.
Oligonucleotides (ONs), including siRNA and antisense ONs, have potentials to become a 
new generation of medicine, due to their high specificity and low toxicity.1 Splice switching 
oligonucleotides (SSOs), a new type of antisense drugs, can hybridize to pre-mRNA 
sequences and block access of other splicing factors to modulate alternative splicing and 
subsequent gene expression.1 A SSO has been used to treat Duchenne muscular dystrophy in 
clinical trials;2 while other SSOs have demonstrated anticancer activity.3 For instance, a 
SSO can redirect Bcl-x splicing from anti-apoptotic Bcl-xL to pro-apoptotic Bcl-xS and 
subsequently induce apoptosis of cancer cells.4 Unfortunately, poor permeability of cell 
membrane to ONs substantially complicate the development of these macromolecules for 
therapeutic applications.5 Recently, cationic lipid, polymers and nanoparticles have been 
widely used for ONs delivery. However, a major fraction of the internalized ONs is trapped 
in endo/lysosomes, which limits their full therapeutic potential.6
To achieve functional delivery of ONs, effective transport of ONs from endosomes into the 
cytosol is indispensable.7 Recently, photochemical internalization (PCI), has been used to 
enhance cytoplasmic delivery of therapeutic macromolecules, such as proteins and ONs.8 In 
the process of PCI, light-activation of the photosensitizer (PS) results in reactive oxygen 
species (ROS)-mediated disruption of the endo/lysosomal membranes followed by the 
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subsequent release of the cargo molecules into the cytosol.9 ONs should colocalize with PSs 
in endocytic vesicles to achieve maximum cytosolic delivery and avoid damage to other 
intracellular compartments.8a, 10 However, in conventional PCI procedures, PSs are given 
separately from the ONs, and thus they may transport to different intracellular sides from the 
ONs’ and then cause side effects by damaging plasma membrane and/or mitochondria.11
In this study, we report that direct conjugation of PS and ONs allows spatial and temporal 
co-localization of the two modalities in the target cells, and thus leads to superior functional 
delivery of ONs. Light-activated delivery of the conjugates of Bcl-x SSO and Chlorin e6 
(Ce6) caused cancer cell killing via Bcl-x splicing switching and photodynamic therapy 
(PDT), leading to a novel strategy for combination therapy of solid tumors (Fig. 1).
Two ONs (ON623 and Bcl-x SSO) were synthesized according to a method described 
previously.12 They were 2′-O-Me phosphorothioate ONs functionalized with a primary 
amine at the 5-end. To conjugate ONs to Ce6, we directly linked 5′ amino-modified ONs to 
Ce6 via an EDC/NHS mediated amine coupling reaction. After that, the products were 
purified with HPLC to remove unreacted ONs and Ce6. ON-Ce6 conjugates eluted after free 
ONs with the retention time of 27.8 and 18.7min, respectively (Fig. S1). MALDI-TOF MS 
data indicated that we obtained right ON conjugates (S2 and S3 and Figs Table S1). 
Absorption spectra of purified ON-Ce6 conjugates showed 3 peaks at 259, 401 and 659nm, 
respectively (Fig. S4). The absorption peak at 259nm is attributed to ONs and the absorption 
peaks at 401nm and 659nm are attributed to Ce6 in the conjugates. Free Ce6 (10μM, in PBS) 
exhibited only 4.1% of the fluorescence intensity of that dissolved in methanol due to the 
aggregation and self-quenching (Fig. S5). However, the ON-Ce6 conjugates (10μM, in PBS) 
showed 96.5% fluorescence (emission peak at 668nm) when compared with free Ce6 
(10uM) in methanol. After the 660nm laser irradiation, dramatic increase in the SOSG 
fluorescence emission was observed for the ON-Ce6 conjugates (1μM, in PBS) when 
compared to that from free Ce6 (1μM, in PBS, Fig. S6). These results demonstrated the great 
solubility of ON-Ce6 conjugates in aqueous solution.
Next, ON623-Ce6 conjugates were complexed with jetPEI, a commercially available 
polyethylenimine (PEI), to form polyplexes for intracellular delivery. Functional delivery of 
ONs was measured in A375/Luc705 cells that were stably transfected by a luciferase 
reporter containing a mutated intron. Successful delivery of ON623 can cause splicing out of 
the intron and allow expression of wild type luciferase. After internalized with polyplexes 
and photoirradiated, dramatically higher luciferase activity was observed when compared to 
non-photoirradiation groups in all N/P ratios. The highest level of luciferase expression was 
detected at N/P ration of 3 (Fig. 2) and it was even higher than Lipofectamine 2000 
lipoplexes of ON623 at the same concentration. The luciferase induction of PEI/ON623-Ce6 
complexs (N/P=3) was dependent on the dose of photoirradiation (Fig. S7). By contrast, 
PEI/ON623 plus free Ce6 did not produce additional luciferase induction compared to single 
treatment of PEI/ON623 (Fig. S8). Size and zeta potential of polyplexes at N/P ration of 3 
were 285.6nm and +7.1mV, respectively (Fig. S9 and S10). The positive charge of PEI/
ON623-Ce6 polyplexes is crucial for efficient intracellular uptake and the N/P ration of 3 
was selected for further experiments. Intracellular uptake efficiency of free Ce6, ON623-Ce6 
conjugates and PEI/623-Ce6 polyplexes (N/P=3) was evaluated in A375/Luc705 cells using 
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flow cytometry. ON623-Ce6 conjugates and PEI/ON623-Ce6 polyplexes allowed for 3.6- 
and 23-fold increase in cellular uptake compared to free Ce6, respectively (Fig. S11). In 
addition, positive PEI did not affect the cellular uptake of free Ce6 (Fig. S12).
Next, confocal laser scanning microscopy was used to observe subcellular distribution of 
PEI/ON623-Ce6 polyplexes after 4-hour incubation with A375/luc705 cells. Most of the 
ON623-Ce6 polyplexes were observed as red dots in the cytoplasm around the nucleus and 
significant colocalization between the polyplexes and lysotracker green was also observed 
(Fig. S13), indicating that most ON623-Ce6 molecules transported to late endosome/
lysosome after cellular entry. To assess endosomal release, PEI/623-Ce6 polyplexes were 
incubated with cells for 4 hours to allow cellular uptake. Once internalized, ON623-Ce6 
remained largely trapped within endosome/lysosomes with little escape to cytosol, as these 
molecules were initially localized in a punctate distribution. Yet, most of the cells displayed 
a cytosolic distribution of ON623-Ce6 conjugates after photoirradiation (Fig. 3). In addition, 
the cells with cytosolic distribution were brighter than those with a punctate distribution, 
which was likely due to the self-quenching of Ce6 when they were trapped within 
endosome/lysosomes.
Photochemical delivery of direct ON-PS conjugates was further examined using a 
therapeutic SSO Bcl-x SSO. Bcl-x pre-mRNA can be alternatively spliced to produce two 
isoforms: anti-apoptotic Bcl-xL and pro-apoptotic Bcl-xS. Bcl-x SSO that is complementary 
to the Bcl-x splice site can shift splicing of Bcl-xL to the Bcl-xS isoform, and was adequate 
to induce apoptosis in cancer cells. PEI/Bcl-x-SSO-Ce6 polyplexes (N/P=3) showed similar 
size and zeta potential with PEI/ON623-Ce6 (Figs. S7 and S8). RT-PCR analysis indicated 
that treatment of PEI/Bcl-x-SSO-Ce6 polyplexes followed by photoirradiation induced a 
dramatic shift in splicing of Bcl-x pre-mRNA from anti-apoptotic Bcl-xL to pro-apoptotic 
Bcl-xS, while control treatments, including PEI/ON623-Ce6 with or without 
photoirradiation, and PEI/Bcl-x-SSO-Ce6 without photoirradiation, had no effect on Bcl-x 
splicing (Fig. 4a).
Finally, cell viability assay was performed after photochemical delivery of Bcl-x SSO in 
A375/luc705 (Fig. 4b) and SKOV3 cells (Fig. S14) in order to assess combinational effects 
of photodynamic therapy and pro-apoptotic splicing switching. Cells treated with PEI/
ON623-Ce6 polyplexes in the absence of photoirradiation served as control, in which no 
obvious dark toxicity was observed. Cells treated with PEI/Bcl-x-SSO-Ce6 polyplexes in the 
absence of photoirradiation showed slightly decreased viability, but the difference was not 
significant. When there was not light-triggered endosomal release, the PEI/Bcl-x-SSO-Ce6 
polyplexes only showed very weak gene therapeutic efficiency. Upon 660nm laser 
irradiation, cells treated with PEI/ON623-Ce6 polyplexes exhibited decreased viability, 
indicating the photodynamic toxicity of direct conjugates of ON and PS. Importantly, the 
combination of photodynamic and gene therapies of the cells by the PEI/Bcl-x-SSO-Ce6 
polyplexes treatment and photoirradiation showed much lower cell viability compared to 
other three treatments. These results revealed that light-induced endosomal escape 
significantly enhanced Bcl-x SSO-mediated toxicity, allowing for concerted photodynamic 
and gene therapies against cancer cells.
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In this study, we have successfully prepared direct conjugate of ON and PS for light-
activated delivery of antisense ONs that leads to combination therapy of cancer. PSs have 
been conjugated to aptamers, single-stranded ONs with tertiary structures that bind to 
specific target molecules, for the purpose of targeted PDTs.13 However, this method has not 
been used for intracellular delivery of therapeutic ONs including siRNA, microRNA, and 
antisense ONs. The direct conjugates of ONs and PSs may provide advantages including 
enhanced water solubility of PSs and consistent spatial distribution of the two modalities in 
the endosome/lysosomes of target cells. After cellular entry using polyplexes, 
photoirradiation controlled the endosomal escape of therapeutic ONs in cancer cells. 
Ultimately, the polyplexes of the conjugates achieved significant growth inhibition of cancer 
cells via concerted photodynamic and gene therapies. This study may thus provide a novel 
platform technology for cytosolic delivery of therapeutic ONs including siRNA, antisense, 
SSOs, and miRNA antagomirs.
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Graphical illustration of PEI/ON-Ce6 polyplexes and laser irradiation mediated cytosolic 
and nuclear delivery of ONs.
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Comparison of luciferase induction (a) and cytotoxicity (b) of PEI/ON623-Ce6 polyplexes 
(50nM of ON623-Ce6) with N/P ratios of 1, 2, 3 and 6, respectively. L2K represents the 
luciferase induction by Lipofectamine 2000 complexes of ON623 (50nM).
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Photoirradiation mediated cytosolic delivery of ONs. Scale bars, 40μm.
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In vitro photoirradiation induced photodynamic and gene therapies in A375/luc705 cells. (a) 
The pre-mRNA of Bcl-xL and Bcl-xs determined by RT-PCR (Reverse transcription 
polymerase chain reaction); 1, PEI/ON623-Ce6; 2, PEI/Bcl-x-SSO-Ce6; 3, PEI/ON623-
Ce6+photoirradiation; 4, PEI/Bcl-x-SSO-Ce6+photoirradiation. (b) In vitro cytotoxicity 
effect in A375/luc705 cells induced by PDT, gene therapy, and combined photodynamic and 
gene therapy. The combined therapy allowed for a significantly higher tumor cell therapeutic 
effect compared to PDT or gene therapy alone. *p<0.05.
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